Lower limits of CRRT dose-intensity: what does the evidence support?

• by Nuttha Lumlertgul, Sean M. Bagshaw

• September 28, 2026

Intravenous-to-enteral drug substitution in the ICU: a single-centre analysis of the potential to reduce the environmental footprint of critical care

• by Clémence Marois, Maxime Gasperment, Adam Celier, Ambre Preteux, Grégoire Gaucher, Léontine Scherer, Nicolas Weiss, Kevin Bihan, Marie Lecronier, Amélie Liou

• September 22, 2026

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

• by Siddharth Singh, Jonas Söderling, Anders Forss, Mathias Rask-Andersen, Jonas Halfvarson, Åsa H. Everhov, Jonas F. Ludvigsson, Ola Olén, SWIBREG study group, Malin Olsson, Pär Myrelid, Henrik Hjortswang, Jonas Bengtsson, Hans Strid, Marie Andersson, Susanna Jäghult, Caroline Nordenvall, Charlotte Hedin, Martin Rejler, Olof Grip, Ulrika L Fagerberg, Karl Mårild, Johann Hreinsson, Pontus Karling

• September 25, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

• by Kathryn Wighton

• September 24, 2026

• 2 min